Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kanhya Ton

Nurse Practitioner Cincinnati, OH Nurse Practitioner

NPI 1891181277 CMS profile 10805739

2123 Auburn Ave Ste 440, Cincinnati, OH 45219

Open in the dashboard

General payments

$2,947

146 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kanhya Ton of Cincinnati, OH is reported in the CMS Open Payments database as having received $2,947 across 146 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $379 11
2023 General $1,204 51
2022 General $964 58
2021 General $400 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kanhya Ton
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Kanhya Ton were reported at $379. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Kanhya Ton Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $400 $135 $40–$426 $132
2022 $964 $152 $48–$470 $149
2023 $1,204 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $379 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $368 19 payments
  2. Dexcom, Inc. $266 6 payments
  3. Inspire Medical Systems, Inc. $223 4 payments
  4. Pfizer Inc. $200 6 payments
  5. Amgen Inc. $186 12 payments
  6. Lilly USA, LLC $175 12 payments
  7. Novo Nordisk Inc $165 11 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $122 7 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $118 8 payments
  10. AstraZeneca Pharmaceuticals LP $111 6 payments
  11. Other $1,013 55 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,947 146 payments
Products named General payments · program years 2021–2025
  1. Dexcom G6 Transmitter $266 6 payments
  2. INSPIRE $223 4 payments
  3. QULIPTA $195 9 payments
  4. NURTEC ODT $159 10 payments
  5. PAXLOVID $155 3 payments
  6. Ozempic $134 9 payments
  7. RYBELSUS $134 9 payments
  8. VRAYLAR $129 8 payments
  9. JARDIANCE $110 6 payments
  10. AtriCure cryoICE cryoSPHERE Cryoablation System $90 1 payment
  11. Other $2,083 125 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 73 drugs

Part D claims

2,719

Median for Nurse Practitioner: 389

Drug cost

$195,026

Median for Nurse Practitioner: $21,885

Branded share of claims

18.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 29 $43,325
Ozempic Semaglutide Brand 17 $29,130
Eliquis Apixaban Brand 37 $24,471
Jardiance Empagliflozin Brand 23 $20,734
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 25 $16,651
Mounjaro Tirzepatide Brand 13 $15,549
Xarelto Rivaroxaban Brand 13 $11,345
Symbicort Budesonide/Formoterol Fumarate Brand 14 $5,307
Janumet Sitagliptin Phos/Metformin Hcl Brand 11 $4,342
Atorvastatin Calcium Generic 327 $2,595

The 10 drugs with the highest cost, of 73 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$4,396

Medicare's payments for the services billed

Medicare patients

74

Average age 74

Services billed

145

49 women, 25 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 41%
Chronic kidney disease 34%
Diabetes 32%
Ischemic heart disease 31%
Osteoporosis 24%
Heart failure 22%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

146 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record